tickerreport.com
Neutralwww.tickerreport.com ·
dare bioscience nasdaqdare issues quarterly earnings results
WB_1453_CONTRACEPTIVESWB_641_REPRODUCTIVE_AND_MATERNAL_HEALTHWB_1452_FAMILY_PLANNINGTAX_DISEASE_PREGNANCY
Topic context
This topic has been covered 357603 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedDare Bioscience, a clinical-stage biotech, beat revenue estimates but faces a cash runway issue. The commercial mechanism is weak: no product revenue yet, and the company needs financing to continue operations. The primary sector is PHARMA_BIOTECH, but the impact is limited to the company's own financing risk and potential dilution.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Dare Bioscience reported Q1 2026 EPS of ($0.21), beating consensus of ($0.33).
- Revenue was $0.15 million, above expectations of $0.03 million.
- First direct product revenue from Flora Sync LF5 expected in June 2026.
- Cash balance of $18.5 million as of Q1 end; insufficient for next 12 months without additional financing.
- Positive DSMB review for Ovaprene; phase II study for DARE-HPV to start in May.